Canavan disease: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Canavan disease
Classification and external resources
ICD-10 E75.2
ICD-9 330.0
OMIM 271900
DiseasesDB 29780
MedlinePlus 001586
MeSH D017825

Canavan disease, also called Canavan-Van Bogaert-Bertrand disease, aspartoacylase deficiency or aminoacylase 2 deficiency,[1] is an autosomal recessive[2] degenerative disorder that causes progressive damage to nerve cells in the brain. This disease is one of a group of genetic disorders called leukodystrophies.

Leukodystrophies are characterized by degeneration of myelin in the phospholipid layer insulating the axon of a neuron. The gene associated with the disorder is located on human chromosome 17.



Canavan disease was first described in 1931 by Myrtelle Canavan.[3]


Although Canavan disease may occur in any ethnic group, it affects persons of Eastern European Jewish ancestry more frequently. About 1/40 individuals of Eastern European (Ashkenazi) Jewish ancestry are carriers.


Canavan disease has an autosomal recessive pattern of inheritance.

Canavan disease is inherited in an autosomal recessive fashion. When both parents are carriers, there is a 25% chance of having an affected child. Genetic counseling and genetic testing is recommended for families with two parental carriers.

Canavan disease is caused by a defective ASPA gene which is responsible for the production of the enzyme aspartoacylase. This enzyme breaks down the concentrated brain molecule N-acetyl aspartate. Decreased aspartoacylase activity prevents the normal breakdown of N-acetyl aspartate, and the lack of breakdown somehow interferes with growth of the myelin sheath of the nerve fibers in the brain. The myelin sheath is the fatty covering that surrounds nerve cells and acts as an insulator, which allows for efficient transmission of nerve impulses.


Symptoms of Canavan disease, which appear in early infancy and progress rapidly, may include mental retardation, loss of previously acquired motor skills, feeding difficulties, abnormal muscle tone (i.e., floppiness or stiffness), poor head control, and megalocephaly (abnormally enlarged head). Paralysis, blindness, or seizures may also occur.


There is no cure for Canavan disease, nor is there a standard course of treatment. Treatment is symptomatic and supportive.


Death usually occurs before age 4 without treatment. Some children may survive into their twenties via newer gene therapy treatments which have extended their life expectancy. In some cases, this helps to temporarily stop the progression of the disease.[citation needed]

Current research

Research involving triacetin supplementation has shown promise in a mouse model.[4] Triacetin, which can be enzymatically cleaved to form acetate, enters the brain more readily than the negatively charged acetate.

A team of researchers headed by Paola Leone are currently at the University of Medicine and Dentistry of New Jersey, in Camden, New Jersey. The brain gene therapy is conducted at Cooper University Hospital. The procedure involves the insertion of six catheters into the brain that deliver a solution containing 600 billion to 900 billion engineered virus particles. The virus, a modified version of AAV, is designed to replace the aspartoacylase enzyme.[5] Children treated with this procedure to date have shown marked improvements, including the growth of myelin with decreased levels of the n-acetyl-aspartate toxin.[6]

See also


  1. ^ Online 'Mendelian Inheritance in Man' (OMIM) 271900
  2. ^ Namboodiri, Am; Peethambaran, A; Mathew, R; Sambhu, Pa; Hershfield, J; Moffett, Jr; Madhavarao, Cn (June 2006). "Canavan disease and the role of N-acetylaspartate in myelin synthesis". Molecular and cellular endocrinology 252 (1-2): 216–23. doi:10.1016/j.mce.2006.03.016. PMID 16647192. 
  3. ^ Canavan MM (1931). "Schilder's encephalitis periaxialis diffusa. Report of a case in a child aged sixteen and one-half months". Archives of Neurology and Psychiatry 25: 299–308. 
  4. ^ Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA (2005). "Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain" (PDF). J. Pharmacol. Exp. Ther. 315 (1): 297–303. doi:10.1124/jpet.105.087536. PMID 16002461. 
  5. ^ Janson, C; Mcphee, S; Bilaniuk, L; Haselgrove, J; Testaiuti, M; Freese, A; Wang, Dj; Shera, D; Hurh, P; Rupin, J; Saslow, E; Goldfarb, O; Goldberg, M; Larijani, G; Sharrar, W; Liouterman, L; Camp, A; Kolodny, E; Samulski, J; Leone, P (July 2002). "Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain". Human gene therapy 13 (11): 1391–412. doi:10.1089/104303402760128612. PMID 12162821. 
  6. ^ "Our Story: The Search for a Cure". Canavan Research Foundation. Retrieved May 14, 2009. 

External links



Got something to say? Make a comment.
Your name
Your email address